Tranexamic acid (TXA) is a widely used plasmin inhibitor that can also
cause a decrease in vascular permeability. We hypothesized that TXA could
improve macular edema that has originated from an increase in retinal vascular
permeability. The aim of this study was to evaluate the efficacy of oral TXA
for macular edema associated with retinal vein occlusion (RVO) or diabetic
macular edema (DME).